Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, MA. They specialize in developing drugs for the treatment of cancer. Merrimack first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in Europe the following year. Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.